Characteristics and Outcome According to Initial Response to Prednisone
| Characteristics . | PGR (n = 37) . | PPR (n = 20) . | P Value . |
|---|---|---|---|
| WBC | |||
| Median (×106/L) | 29,000 | 144,900 | .0016* |
| Min/max (×106/L) | 2,200/450,000 | 6,200/572,200 | |
| BFM RF (median)† | 1.20 | 1.32 | .11* |
| Age (median; yr) | 6.88 | 10.0 | .02* |
| No. of males (%) | 26 (70) | 12 (60) | .56‡ |
| Breakpoint2-153 | |||
| m-BCR (n; %) | 19 (79) | 10 (71) | .70‡ |
| M-BCR (n; %) | 5 (21) | 4 (29) | |
| Common ALL (n; %) | 28 (76) | 17 (85) | .51‡ |
| Blast cell count on day 8 | |||
| Median2-155(×106/L) | 48 | 3,654 | .0001* |
| Min/max (×106/L) | 0/828 | 1,067/124,000 | |
| CR1 after induction (n; %) | 37 (100) | 6 (30) | <.0001‡ |
| CR achieved at any time (n; %) | 37 (100) | 15 (75) | .004‡ |
| Relapses¶# (n; %) | 12 (32) | 10 (67) | |
| Death in CR1¶2-160 (n; %) | 4 (11) | 3 (20) | |
| In CR1 (n) | 21 | 2 | |
| Alive (n) | 26 | 2 |
| Characteristics . | PGR (n = 37) . | PPR (n = 20) . | P Value . |
|---|---|---|---|
| WBC | |||
| Median (×106/L) | 29,000 | 144,900 | .0016* |
| Min/max (×106/L) | 2,200/450,000 | 6,200/572,200 | |
| BFM RF (median)† | 1.20 | 1.32 | .11* |
| Age (median; yr) | 6.88 | 10.0 | .02* |
| No. of males (%) | 26 (70) | 12 (60) | .56‡ |
| Breakpoint2-153 | |||
| m-BCR (n; %) | 19 (79) | 10 (71) | .70‡ |
| M-BCR (n; %) | 5 (21) | 4 (29) | |
| Common ALL (n; %) | 28 (76) | 17 (85) | .51‡ |
| Blast cell count on day 8 | |||
| Median2-155(×106/L) | 48 | 3,654 | .0001* |
| Min/max (×106/L) | 0/828 | 1,067/124,000 | |
| CR1 after induction (n; %) | 37 (100) | 6 (30) | <.0001‡ |
| CR achieved at any time (n; %) | 37 (100) | 15 (75) | .004‡ |
| Relapses¶# (n; %) | 12 (32) | 10 (67) | |
| Death in CR1¶2-160 (n; %) | 4 (11) | 3 (20) | |
| In CR1 (n) | 21 | 2 | |
| Alive (n) | 26 | 2 |
*Wilcoxon test.
BFM RF was not available from 1 patient.
Fisher exact test.
In 2 patients without data on PRED-response, m-BCR and M-BCR was detected in 1 patient each.
The exact number of blasts was reported from 33 patients with PGR and from 17 patients with PPR.
¶Percentage relates to the number of patients that achieved CR.
#Among patients with PGR, 10 relapses occurred in the BM, 1 in BM/bone, and 1 in testis; among patients with PPR, there were 8 systemic and 2 combined relapses (BM/skin; BM/CNS). Among the patients without PRED response evaluation, 2 isolated systemic recurrences were noted. For statistical comparison of events in PGR and PPR, see Fig 3.
All lethal complications were associated with allogeneic BMT; in addition, there was one lethal BMT complication among the 4 patients who were not evaluable for the day-8 response.